Akoya Biosciences (AKYA) News Today $1.49 +0.04 (+2.76%) Closing price 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Akoya Biosciences downgraded to Equal Weight from Overweight at StephensMarch 27 at 12:17 PM | markets.businessinsider.comTikvah intends to vote against Quanterix’s proposed merger with AkoyaMarch 26 at 1:37 PM | markets.businessinsider.comAkoya Biosciences (NASDAQ:AKYA) Given Equal Weight Rating at StephensStephens restated an "equal weight" rating and issued a $1.80 price target (down from $3.50) on shares of Akoya Biosciences in a report on Tuesday.March 26 at 10:51 AM | marketbeat.comStephens & Co. Downgrades Akoya Biosciences (AKYA)March 26 at 3:31 AM | msn.comAkoya Biosciences (NASDAQ:AKYA) Given "Equal Weight" Rating at StephensMarch 26 at 2:33 AM | americanbankingnews.comTikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya BiosciencesMarch 24 at 4:10 PM | finance.yahoo.comAkoya Biosciences (AKYA) to Release Quarterly Earnings on MondayAkoya Biosciences (NASDAQ:AKYA) will be releasing earnings after the market closes on Monday, March 31, Financial Modeling Prep reports.March 24 at 2:11 AM | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from StephensStephens reaffirmed an "overweight" rating and issued a $3.50 price target on shares of Akoya Biosciences in a research note on Tuesday.March 19, 2025 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Given "Overweight" Rating at StephensMarch 19, 2025 | americanbankingnews.comAkoya Biosciences (AKYA) Receives a Hold from Craig-HallumMarch 19, 2025 | markets.businessinsider.comAkoya Biosciences (NASDAQ:AKYA) Releases Earnings Results, Misses Estimates By $0.02 EPSAkoya Biosciences (NASDAQ:AKYA - Get Free Report) issued its earnings results on Monday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%.March 18, 2025 | marketbeat.comBrokerages Set Akoya Biosciences, Inc. (NASDAQ:AKYA) Target Price at $3.98March 18, 2025 | americanbankingnews.comKent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings CallMarch 17, 2025 | tmcnet.comAkoya Biosciences reports Q4 EPS (17c), consensus (16c)March 17, 2025 | markets.businessinsider.comAkoya Reports Fourth Quarter of 2024 and Full Year Financial ResultsMarch 17, 2025 | globenewswire.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of "Hold" by BrokeragesShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average 12 month price objective among brokersMarch 15, 2025 | marketbeat.comAkoya Biosciences downgraded to Neutral from Overweight at Piper SandlerMarch 5, 2025 | markets.businessinsider.comSVB Wealth LLC Buys Shares of 515,398 Akoya Biosciences, Inc. (NASDAQ:AKYA)SVB Wealth LLC bought a new stake in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 515,398 shares of the company's stock, valued at approximately $1,180,000. SVB WealtMarch 3, 2025 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 60.1% in FebruaryAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 3,250,000 shares, a growth of 60.1% from the January 31st total of 2,030,000 shares. Based on an average daily volume of 666,100 shares, the short-interest ratio is currently 4.9 days. Currently, 15.8% of the shares of the stock are short sold.March 2, 2025 | marketbeat.comAkoya Biosciences (AKYA) Projected to Post Earnings on MondayAkoya Biosciences (NASDAQ:AKYA) will be releasing earnings before the market opens on Monday, March 3.February 24, 2025 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Hold" from AnalystsShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and two have issued a buy ratiFebruary 18, 2025 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest UpdateAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,030,000 shares, a decrease of 6.5% from the January 15th total of 2,170,000 shares. Approximately 9.9% of the company's shares are short sold. Based on an average daily trading volume, of 648,900 shares, the days-to-cover ratio is presently 3.1 days.February 17, 2025 | marketbeat.comAkoya Biosciences unveils strategic product roadmapFebruary 6, 2025 | markets.businessinsider.comAkoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology PanelsFebruary 5, 2025 | globenewswire.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 24.0% in JanuaryAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 2,170,000 shares, a growth of 24.0% from the December 31st total of 1,750,000 shares. Based on an average daily volume of 597,700 shares, the short-interest ratio is presently 3.6 days. Currently, 4.4% of the shares of the stock are short sold.February 1, 2025 | marketbeat.comAkoya Biosciences selects Argonaut Manufacturing as IVD manufacturing partnerJanuary 29, 2025 | markets.businessinsider.comAkoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing PartnerJanuary 28, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Akoya Biosciences (AKYA) and HCA Healthcare (HCA)January 25, 2025 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of "Hold" from AnalystsAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has been given an average rating of "Hold" by the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The aJanuary 24, 2025 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Canaccord Genuity GroupCanaccord Genuity Group downgraded shares of Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday.January 15, 2025 | marketbeat.comQuanterix price target lowered to $11 from $15 at TD CowenJanuary 13, 2025 | markets.businessinsider.comHold Rating Suggested Amid Acquisition Uncertainties and Growth Concerns for Akoya BiosciencesJanuary 13, 2025 | markets.businessinsider.comQTRX-Akoya Acquisition: Cautious Hold Amid Strategic Synergy and Integration UncertaintiesJanuary 11, 2025 | markets.businessinsider.comAkoya Biosciences Inc AKYAJanuary 11, 2025 | morningstar.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya ...January 10, 2025 | businesswire.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAJanuary 10, 2025 | businesswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Akoya Biosciences, Inc. BuyoutJanuary 10, 2025 | markets.businessinsider.comAKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. ...January 10, 2025 | gurufocus.comQuanterix Agrees to Buy Life Sciences Firm Akoya BiosciencesJanuary 10, 2025 | msn.comTraders Digest Strong Jobs Growth as US Equity Futures Drop Pre-BellJanuary 10, 2025 | msn.comAkoya climbs after merger deal with QuanterixJanuary 10, 2025 | seekingalpha.comAKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to ShareholdersJanuary 10, 2025 | tmcnet.comQuanterix To Buy Akoya Biosciences In All Stock Deal; QTRX Up In Pre-MarketJanuary 10, 2025 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of "Hold" by AnalystsShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given an average recommendation of "Hold" by the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and three have assigned a buy raDecember 30, 2024 | marketbeat.comShort Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 20.7%Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,810,000 shares, an increase of 20.7% from the November 30th total of 1,500,000 shares. Approximately 9.1% of the shares of the stock are short sold. Based on an average daily volume of 229,100 shares, the days-to-cover ratio is presently 7.9 days.December 29, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 18.1% in NovemberAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,500,000 shares, an increase of 18.1% from the November 15th total of 1,270,000 shares. Based on an average daily volume of 228,600 shares, the short-interest ratio is currently 6.6 days. Currently, 7.5% of the shares of the stock are sold short.December 14, 2024 | marketbeat.comAkoya Biosciences, NeraCare enter exclusive global license agreementDecember 11, 2024 | markets.businessinsider.comAkoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsDecember 10, 2024 | globenewswire.comNature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry MilestoneDecember 10, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Hold" from BrokeragesAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has earned an average rating of "Hold" from the eight analysts that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-December 5, 2024 | marketbeat.com Remove Ads Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Media Mentions By Week AKYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKYA News Sentiment▼0.380.78▲Average Medical News Sentiment AKYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKYA Articles This Week▼102▲AKYA Articles Average Week Remove Ads Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QTRX News Today QSI News Today AEHR News Today FEIM News Today MASS News Today KEQU News Today NAUT News Today RPID News Today SEER News Today INTT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKYA) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKYA Stock Free AKYA Stock Alerts